Get the Stockscreener App
16.21
4.20%
-0.71
After Hours:
16.78
0.57
+3.52%
Generate Biomedicines Inc stock is traded at $16.21, with a volume of 860.27K.
It is down -4.20% in the last 24 hours and up +25.95% over the past month.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
See More
Previous Close:
$16.92
Open:
$16.93
24h Volume:
860.27K
Relative Volume:
1.18
Market Cap:
$2.08B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-7.5206
EPS:
-2.1554
Net Cash Flow:
-
1W Performance:
-3.91%
1M Performance:
+25.95%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.18
$17.33
1-Week Range:
$16.18
$17.89
52-Week Range:
$11.00
$18.18
Generate Biomedicines Inc Stock (GENB) Company Profile
Name
Generate Biomedicines Inc
Sector
Industry
Phone
888-469-0055
Address
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
16.21 | 2.17B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | H.C. Wainwright | Buy |
| Mar-24-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-24-26 | Initiated | Goldman | Buy |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Mar-24-26 | Initiated | Morgan Stanley | Overweight |
| Mar-24-26 | Initiated | Piper Sandler | Overweight |
View All
Generate Biomedicines Inc Stock (GENB) Latest News
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday - The Motley Fool
If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
EBITDA of Generate Biomedicines, Inc. – BX:GENB - TradingView
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
GENBGenerate Biomedicines Inc Dividends - Finviz
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Price to book forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to book forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Q&A: Generate Biomedicines CTO talks AI advancements - TechTarget
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Index - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Value Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Growth Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 3000E Growth Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 3000 Index - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS:GENB) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Generate Biomedicines stock ends week back above IPO price as volume jumps - TechStock²
Transcript : Generate Biomedicines, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 03 - marketscreener.com
Enterprise value to EBITDA forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Enterprise value to EBIT forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Enterprise value to EBIT forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
Generate Biomedicines, Inc. Actuals & Estimates (NASDAQ:GENB) - TradingView
Generate Biomedicines, Inc. Actuals & Estimates (BOATS:GENB) - TradingView
Price to sales forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
Price to earnings forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
GENB Forecast — Price Target — Prediction for 2027 - TradingView
Guggenheim Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB) - Yahoo Finance
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts - Sahm
AdvanCell takes all of IQHQ’s 128,000-sq-ft Andover site - Stock Titan
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to S&P TMI Index - marketscreener.com
Generate Biomedicines, Inc. (GENB) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Generate Biomedicines (GENB) Q1 2026 earnings summary - Quartr
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Generate Biomedicines (GENB) News Flow - Moomoo
Generate Biomedicines Surges 9.69%: Breaking Resistance Levels in Biotech RallyIntraday Trade Ideas - newsline.com
Generate Biomedicines (GENB) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Generate Biomedicines, Inc. (GENB) Market Cap - Zacks Investment Research
Generate Biomedicines (GENB) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
GENB Price Today: Generate Biomedicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Why Is Generate Biomedicines, Inc. (GENB) Stock Down Today? - Meyka
Generate Biomedicines (GENB) Tumbles 7% as Selling Pressure Mounts – Key Support Levels in FocusSentiment Shift - newsline.com
Why Is Generate Biomedicines, Inc. (GENB) Stock Up Today? - Meyka
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains - Yahoo Finance
Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x - simplywall.st
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Generate Biomedicines Inc. (GENB) Q1 2026 Earnings: Wider-than-Expected Loss Underscores Pre-Revenue Development StageEarnings Analysis - newsline.com
Generate Biomedicines Inc Stock (GENB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Generate Biomedicines Inc Stock (GENB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grous Beth | Chief People Officer |
Mar 02 '26 |
Buy |
16.00 |
300 |
4,800 |
300 |
| Silvers Jason | President & CFO |
Mar 02 '26 |
Buy |
16.00 |
2,000 |
32,000 |
1,000 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
| Mendillo Jane L | Director |
Mar 02 '26 |
Buy |
16.00 |
1,500 |
24,000 |
1,500 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):